FDA Inspection
Hikma Pharmaceuticals USA Inc.Hikma Pharmaceuticals USA Inc. – FDA Inspection, Sep 10, 2019
Record Details
This FDA Inspection record concerns Hikma Pharmaceuticals USA Inc., with an inspection on September 10, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
- Yvesna C. Blaise (Issuing Officer)
View Company Profile
ID · 607fb2a5-7932-4aff-a16c-1afe2023de82
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1106822
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Hikma Pharmaceuticals USA Inc.
18| Date | Classification | Office | Project area |
|---|---|---|---|
| May 13, 2026 | Not classified | New Jersey District Office | |
| June 12, 2024 | VAI | Drug Quality Assurance | |
| November 3, 2023 | VAI | Drug Quality Assurance | |
| July 7, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 14, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Hikma Pharmaceuticals USA Inc.
- FDA Inspection 1304368 - 2026-05-13
- FDA Inspection 1237333 - 2024-06-12
- FDA Inspection 1222115 - 2023-11-03
- FDA Inspection 1176451 - 2022-07-07
- FDA Inspection 1067645 - 2018-09-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.